“钠-葡萄糖共转运蛋白-2（SGLT-2）抑制剂的心肾保护作用已被多项大规模、多中心临床试验证实。2023年4月，亚太肾脏病学会颁布了《亚太地区SGLT-2抑制剂的专家共识》（以下简称本共识），结合亚太地区的文化与风俗，聚焦于SGLT-2抑制剂的应用 ...

Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors ...

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

“2型糖尿病，这一全球性流行病，正悄然影响着近5亿成年人的健康，带来沉重的疾病负担。近年来，科学家们不断探索2型糖尿病与肿瘤之间的复杂关系——高胰岛素血症、高血糖状态和慢性炎症等多种机制，可能成为肿瘤发生和发展的“推手”。那么，作为新型降糖药物的钠- ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

随着患者使用 SGLT2 抑制剂时间的延长，进展为重度主动脉瓣狭窄的风险逐渐降低：使用至少 3 个月 、 6 个月、 12个月 的，进展为重度主动脉瓣狭窄风险分别降低 46%、 52%和 72%。 研究者分析 ，其作用机制可能是多种途径共同作用的结果，有研究发现， 钙化的主动脉瓣叶上 SGLT2 受体过度表达，可以推断，通过抑制这些受体来减轻炎症和细胞内钙含量，能够降低病情进展速度。 研究者还指出 ...